| TNBC | Triple Negative Breast Cancer |
| DTCs | Disseminated Tumor Cells |
| NACT | Neoadjuvant Chemotherapy |
| pCR | Pathologic Complete Remission |
| CK | Cytokeratin |
| Vim | Vimentin |
| HER2 | Human Epidermal Growth Factor Receptor 2 |
| PD-L1 | Programmed Cell Death 1 Ligand 1 |
| BM | Bone Marrow |
| EMT | Epithelial–Mesenchymal Transition |
| ER | Estrogen Receptor |
| PR | Progesterone Receptor |
| IF | Immunofluorescence |
| IHC | Immunohistochemical |
| FISH | Fluorescence In Situ Hybridization |
| CISH | Chromogenic In Situ Hybridization |
| CNB | Core Needle Biopsy |
| DMEM | Dulbecco’s Modified Eagle Medium |
| RPMI | Roswell Park Memorial Institute |
| PBS | Phosphate-Buffered Saline |
| DAPI | 4′,6′-Diamidin-2-phenylindol |
| APC | Allophycocyanin |
| FITC | Fluoresceinisothiocyanat |
| PE | Phycoerythrin |
| TPS | Tumor Proportion Score |
| CPS | Combined Positive Score |
| CTCs | Circulating Tumor Cells |